Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

ARS Pharmaceuticals (SPRY) FCF Margin (2022 - 2025)

ARS Pharmaceuticals' FCF Margin history spans 4 years, with the latest figure at 154.82% for Q4 2025.

  • For Q4 2025, FCF Margin fell 20279.0% year-over-year to 154.82%; the TTM value through Dec 2025 reached 203.14%, down 21771.0%, while the annual FY2025 figure was 203.14%, 21771.0% down from the prior year.
  • FCF Margin for Q4 2025 was 154.82% at ARS Pharmaceuticals, down from 127.77% in the prior quarter.
  • Across five years, FCF Margin topped out at 47.96% in Q4 2024 and bottomed at 166690.0% in Q2 2023.
  • The 4-year median for FCF Margin is 875.72% (2024), against an average of 19835.07%.
  • The largest annual shift saw FCF Margin tumbled -16519151bps in 2023 before it soared 16525080bps in 2024.
  • A 4-year view of FCF Margin shows it stood at 3006.35% in 2022, then crashed by -5445bps to 166690.0% in 2023, then soared by 100bps to 47.96% in 2024, then plummeted by -423bps to 154.82% in 2025.
  • Per Business Quant, the three most recent readings for SPRY's FCF Margin are 154.82% (Q4 2025), 127.77% (Q3 2025), and 288.61% (Q2 2025).